Inpharma 1655 - 13 Sep 2008

■ COL 144,* a first-in-class neurally acting migraineagent, is safe and effective in relieving migraine,according to phase II results presented at theEuropean Headache and Migraine Trust InternationalCongress. 130 patients were randomly assigned toreceive either COL 144 2.5–45mg or placebo as anintravenous infusion over 20 mins as first-linetreatment for an acute migraine attack. At 2 hourspostdose, headache response was observed in ahigher proportion of patients who received COL 14410mg, 20mg, 30mg or 45mg than placebo (54.2–75%vs 45.2%), with a statistically significant linearassociation between response rates and dosage levels.COL 144 was generally well tolerated, and no patientreported triptan-like chest symptoms in relation totreatment.* CoLucid Pharmaceuticals; phase II in the US for migraine

CoLucid Pharmaceuticals Inc. Phase II Results of COL-144 Presented atEuropean Headache and Migraine Trust International Congress 2008. MediaRelease : 6 Sep 2008. Available from: URL: http://www.colucid.com 809092875

1

Inpharma 13 Sep 2008 No. 16551173-8324/10/1655-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved